- 5 hrs ago How Can Birth Control Pills Affect A Woman's Life
- 23 hrs ago Intensive Blood Pressure Management At 50 Likely To Preserve Brain Health
- 24 hrs ago Alia Bhatt Keeps It Chic And Sassy For The Prada Song Launch
- 1 day ago Real Stories Of Monogamous Couples: When And Why They Chose to Be Monogamous
- News Bhutan's Leader of Opposition meets Modi
- Sports NADA to start testing players during Duleep games, BCCI want only doctors as DCOs
- Movies Happy Birthday Gulzar Sahab: These Songs Penned By Him Are PURE GEM!
- Technology Office vs Office 365: Key differences you should know
- Automobiles Okinawa Offers Special Discounts On Their Electric Scooter Range This Festive Season
- Finance Pokemon Cards Sold For Over $1,00,000 In An Online Auction
- Education CA IPCC Result 2019 Likely To Be Announced On Aug 23 Or 24
- Travel Cycling for beginners: The basics any beginner cyclists should know
Scientists have developed a new antibody-based test that can help differentiate Zika virus infections from infections caused by similar viruses such as dengue and West Nile.
Zika is a mosquito-borne disease and is linked to severe congenital birth defects.
The new antibody-based test, developed by researchers at the University of California - Berkeley and biotechnology company Humabs BioMed, has very high sensitivity (91.8 per cent) and specificity (95.9 per cent) for identifying Zika virus infections.
"The whole world has been in urgent need of a serological method to distinguish dengue virus from Zika virus infections, and this (is) the first to have such high sensitivity and specificity in dengue-endemic regions," said Eva Harris, Professor at UC-B.
To develop the test, Humabs generated a new human antibody to the Zika virus.
The researchers then implemented the test on samples from Zika patients, with or without prior exposure to dengue virus, and samples from dengue patients infected either once or more than once with different types of the dengue virus.
The data, published in the journal Proceedings of the National Academy of Sciences, showed that the test was highly sensitive, specific and robust.
"These results support that the antibody-based assay that we have developed is highly effective in detecting both recent and past Zika virus infections and in discriminating Zika from other flavivirus infections," said Davide Corti, senior Vice President and Chief Scientific Officer from Humabs BioMed.
"This novel test has the potential to become an effective, simple and low-cost solution for Zika surveillance programs, prevalence studies and clinical intervention trials in flavivirus-endemic areas," Corti added.
Inputs From IANS